Balanitis with palmoplantar erythrodysesthesia: A case report and review of literature

Khalid Al-Husain; Zahra Alsindi; Nadya Al-Faraidy; Ahmad Qudaih; Gamil Mohammad

doi:10.29333/ejgm/15996

Full Text (PDF)

Khalid Al-Husain ¹ , Zahra Alsindi ² ^* , Nadya Al-Faraidy ³ , Ahmad Qudaih ⁴ , Gamil Mohammad ³

More Detail

¹ Department of Dermatology, College of Medicine, Imam Abdulrahman Bin Faisal University, Dammam, SAUDI ARABIA² College of Medicine, King Faisal University, Alhasa, SAUDI ARABIA³ Dermatology Section, Department of Medicine, King Fahad Specialist Hospital, Dammam, SAUDI ARABIA⁴ Department of Medical Oncology, King Fahad Specialist Hospital, Dammam, SAUDI ARABIA^* Corresponding Author

Abstract

Capecitabine a pro-drug of 5-fluorouracil is a commonly used chemotherapeutic agent for the treatment of many cancers. A common side effect of this agent is palmar-plantar erythrodysesthesia. However, genital ulceration is an unusual side effect reported only a few times in the literature. Herein, we present a patient with unusual genital ulceration and palmoplantar erythrodysesthesia following capecitabine chemotherapy and review similar cases from the literature and review their pathophysiology and management strategies.

Keywords

capecitabine
palmar-plantar erythrodysesthesia
5-fluorouracil
genital ulceration
chemotherapy
adverse reaction

License

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article Type: Case Report

ELECTRON J GEN MED, Volume 22, Issue 2, April 2025, Article No: em636

https://doi.org/10.29333/ejgm/15996

Publication date: 01 Mar 2025

Online publication date: 18 Feb 2025

Article Views: 191

Article Downloads: 64

Open Access References How to cite this article

References

Abushullaih S, Saad ED, Munsell M, Hoff PM. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: A single-institution experience. Cancer Invest. 2002;20(1):3-10. https://doi.org/10.1081/CNV-120000360 PMid:11853000
de Queiroz MVR, de Medeiros ACTR, Toledo SP, de Abreu Sarmenghi KD, de Vasconcellos VF. Hand-foot syndrome caused by capecitabine: Incidence, risk factors and the role of dermatological evaluation. Ecancermedicalscience. 2022;16:1390. https://doi.org/10.3332/ecancer.2022.1390 PMid:35919225 PMCid:PMC9300399
Chiara S, Nobile MT, Barzacchi C, et al. Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. Eur J Cancer. 1997;33(6):967-9. https://doi.org/10.1016/S0959-8049(96)00497-2 PMid:9291822
Nagore E, Insa A, Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000;1(4):225-34. https://doi.org/10.2165/00128071-200001040-00004 PMid:11702367
Eich D, Scharffetter-Kochanek K, Eich HT, Tantcheva-Poor I, Krieg T. Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer. Am J Clin Oncol. 2002;25(6):599-602. https://doi.org/10.1097/00000421-200212000-00015 PMid:12478008
Sapp CM, DeSimone P. Palmar-plantar erythrodysesthesia associated with scrotal and penile involvement with capecitabine. Clin Colorectal Cancer. 2007;6(5):382-5. https://doi.org/10.3816/CCC.2007.n.008 PMid:17311704
Fleta-Asín B, Alcántara-González J, Alonso-Castro L, Truchuelo-Díez M, Jaén-Olasolo P. Genital erythrodysesthesia as a severe manifestation of capecitabine therapy: A report of 3 cases. Arch Dermatol. 2011;147(9):1123-4. https://doi.org/10.1001/archdermatol.2011.257 PMid:21931065
Ljubojevic Hadzavdic S, Stulhofer Buzina D, Murtezani I, Skerlev M. Unusual scrotal and penile ulcerations together with palmar-plantar erythrodysesthesia syndrome in a patient with metastatic colon carcinoma treated with capecitabine. J Eur Acad Dermatol Venereol. 2017;31(6):e304-6. https://doi.org/10.1111/jdv.14090 PMid:27987319
Hu HP, Corkum MT, Perera F. Palmar-plantar erythrodysesthesia with genital involvement secondary to capecitabine chemoradiotherapy: A case report. Cureus. 2018;10(12):e3704. https://doi.org/10.7759/cureus.3704 PMid:30788193 PMCid:PMC6373891
Dricken J, Pettke E, Griffin JA, Li HY, Mehta V. Scrotal and penile erythrodysesthesia associated with neoadjuvant capecitabine chemoradiation. Cureus. 2020;12(4):e7724. https://doi.org/10.7759/cureus.7724 PMid:32432002 PMCid:PMC7234053
Chan BL, Wang T. Capecitabine-induced genital hand-foot syndrome treated with topical tacrolimus. Cureus. 2024;16(4):e57570. https://doi.org/10.7759/cureus.57570
Heo YS, Chang HM, Kim TW, et al. Hand-foot syndrome in patients treated with capecitabine-containing combination chemotherapy. J Clin Pharmacol. 2004;44(10):1166-72. https://doi.org/10.1177/0091270004268321 PMid:15342618
Brant JM, Wilkes GM, Doyle D. Palmar-plantar erythrodysesthesia. Clin J Oncol Nurs. 2005;9(1):103-6. https://doi.org/10.1188/05.CJON.103-106 PMid:15751504
Apisarnthanarax N, Duvic MM. Eccrine squamous syringometaplasia. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei cancer medicine. 6th ed. Hamilton (ON): BC Decker; 2003.
Zhang S, Wang Z, Fan S, et al. Capecitabine can induce T cell apoptosis: A potential immunosuppressive agent with anti-cancer effect. Front Immunol. 2021;12:737849. https://doi.org/10.3389/fimmu.2021.737849 PMid:34557199 PMCid:PMC8452994
Dean L, Kane M. Capecitabine therapy and DPYD genotype. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, editors. Medical genetics summaries. Bethesda (MD): National Center for Biotechnology Information; 2012.
Li JB, Lin ZC, Wong MCS, Wang HHX, Li M, Li S. A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society. BMC Med. 202226; 20(1):320. https://doi.org/10.1186/s12916-022-02516-9 PMid:36156186 PMCid:PMC9511760
Chen M, Zhang L, Wang Q, Shen J. Pyridoxine for prevention of hand-foot syndrome caused by chemotherapy: A systematic review. PLoS One. 2013;8(8):e72245. https://doi.org/10.1371/journal.pone.0072245 PMid:23977264 PMCid:PMC3748123
Yap Y-S, Kwok L-L, Syn N, et al. Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: A randomized clinical trial. JAMA Oncol. 2017;3(11):1538-45. https://doi.org/10.1001/jamaoncol.2017.1269 PMid:28715540 PMCid:PMC5710192
Kang Y-K, Lee SS, Yoon DH, et al. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: Results of a randomized, double-blind, placebo-controlled study. J Clin Oncol. 2010; 28(24):3824-9. https://doi.org/10.1200/JCO.2010.29.1807 PMid:20625131
Macedo LT, Lima JPN, Dos Santos LV, Sasse AD. Prevention strategies for chemotherapy-induced hand-foot syndrome: A systematic review and meta-analysis of prospective randomised trials. Support Care Cancer. 2014;22(6):1585-93. https://doi.org/10.1007/s00520-014-2129-z PMid:24463616
Santhosh A, Sharma A, Bakhshi S, et al. Topical diclofenac for prevention of capecitabine-associated hand-foot syndrome: A double-blind randomized controlled trial. J Clin Oncol. 2024;42(15):1821-9. https://doi.org/10.1200/JCO.23.01730 PMid:38412399
Meadows KL, Rushing C, Honeycutt W, et al. Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: A pilot study. Support Care Cancer. 2015; 23(5):1311-9. https://doi.org/10.1007/s00520-014-2465-z PMid:25341548 PMCid:PMC4973630
Abdelalim LR, Elnaggar YSR, Abdallah OY. Oleosomes encapsulating sildenafil citrate as potential topical nanotherapy for palmar plantar erythrodysesthesia with high ex vivo permeation and deposition. AAPS PharmSciTech. 2020;21(8):310. https://doi.org/10.1208/s12249-020-01862-2 PMid:33164131
Pendharkar D, Goyal H. Novel & effective management of capecitabine induced hand foot syndrome. J Clin Oncol. 2004;22(14 Suppl):8105. https://doi.org/10.1200/jco.2004.22.90140.8105
Hofheinz RD, Gencer D, Schulz H, et al. Mapisal versus urea cream as prophylaxis for capecitabine-associated hand-foot syndrome: A randomized phase III trial of the AIO quality of life working group. J Clin Oncol. 2015; 33(22):2444-9. https://doi.org/10.1200/JCO.2014.60.4587 PMid:26124485
Elyasi S, Shojaee FSR, Allahyari A, Karimi G. Topical silymarin administration for prevention of capecitabine-induced hand-foot syndrome: A randomized, double-blinded, placebo-controlled clinical trial. Phytother Res. 2017;31(9):1323-9. https://doi.org/10.1002/ptr.5857 PMid:28635153

How to cite this article

Vancouver

Al-Husain K, Alsindi Z, Al-Faraidy N, Qudaih A, Mohammad G. Balanitis with palmoplantar erythrodysesthesia: A case report and review of literature. ELECTRON J GEN MED. 2025;22(2):em636. https://doi.org/10.29333/ejgm/15996

APA

Al-Husain, K., Alsindi, Z., Al-Faraidy, N., Qudaih, A., & Mohammad, G. (2025). Balanitis with palmoplantar erythrodysesthesia: A case report and review of literature. Electronic Journal of General Medicine, 22(2), em636. https://doi.org/10.29333/ejgm/15996

AMA

Al-Husain K, Alsindi Z, Al-Faraidy N, Qudaih A, Mohammad G. Balanitis with palmoplantar erythrodysesthesia: A case report and review of literature. ELECTRON J GEN MED. 2025;22(2), em636. https://doi.org/10.29333/ejgm/15996

Chicago

Al-Husain, Khalid, Zahra Alsindi, Nadya Al-Faraidy, Ahmad Qudaih, and Gamil Mohammad. "Balanitis with palmoplantar erythrodysesthesia: A case report and review of literature". Electronic Journal of General Medicine 2025 22 no. 2 (2025): em636. https://doi.org/10.29333/ejgm/15996

Harvard

Al-Husain, K., Alsindi, Z., Al-Faraidy, N., Qudaih, A., and Mohammad, G. (2025). Balanitis with palmoplantar erythrodysesthesia: A case report and review of literature. Electronic Journal of General Medicine, 22(2), em636. https://doi.org/10.29333/ejgm/15996

MLA

Al-Husain, Khalid et al. "Balanitis with palmoplantar erythrodysesthesia: A case report and review of literature". Electronic Journal of General Medicine, vol. 22, no. 2, 2025, em636. https://doi.org/10.29333/ejgm/15996